Cargando…

Effect of Metformin on Breast Density in Overweight/Obese Premenopausal Women

BACKGROUND: This study investigated the effects of metformin on breast density in overweight/obese premenopausal women. METHODS: Overweight/obese premenopausal women (n=120) were randomly assigned to the metformin or placebo group, and all women received lifestyle interventions. The outcomes include...

Descripción completa

Detalles Bibliográficos
Autores principales: Leng, Weiling, Pu, Danlan, Jiang, Juan, Lei, Xiaotian, Wu, Qinan, Chen, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572728/
https://www.ncbi.nlm.nih.gov/pubmed/34764661
http://dx.doi.org/10.2147/DMSO.S330625
_version_ 1784595274894671872
author Leng, Weiling
Pu, Danlan
Jiang, Juan
Lei, Xiaotian
Wu, Qinan
Chen, Bing
author_facet Leng, Weiling
Pu, Danlan
Jiang, Juan
Lei, Xiaotian
Wu, Qinan
Chen, Bing
author_sort Leng, Weiling
collection PubMed
description BACKGROUND: This study investigated the effects of metformin on breast density in overweight/obese premenopausal women. METHODS: Overweight/obese premenopausal women (n=120) were randomly assigned to the metformin or placebo group, and all women received lifestyle interventions. The outcomes included weight, BMI, FPG, FIN, glucose, HOMA-IR, LDL-C, HDL-C, TG, TC, SBP, DBP, FSH, E, AD, and the BIRADS grade, and the incidence of breast cancer was assessed by pathological biopsy and BIRADS grade greater than 4. RESULTS: In total, 120 overweight/obese women completed the 1-year trial. Seven patients had a BIRADS grade greater than 4, including 5 patients who were biopsy positive, in the control group, and 2 patients had a BIRADS grade greater than 4, including 1 patient who was biopsy positive, in the metformin group. Compared with those in the control group, the body weight, BMI, FIN, FPG, HOMA-IR, TC, BIRADS grade and positive pathological biopsy rate in the metformin group were significantly decreased (P<0.05), while AD was significantly increased (P<0.05). The correlation analysis indicated that the BIRADS grade was significantly correlated with weight, BMI, FPG, FIN, HOMA-IR, SBP, AD and the positive pathological biopsy rate, and the positive pathological biopsy rate was significantly correlated with weight, BMI, HOMA-IR, SBP, AD and BIRADS grade. The logistic regression analysis revealed that the BIRADS grade was significantly correlated with the positive pathological biopsy rate and AD and that the positive pathological biopsy rate was significantly correlated with the BIRADS grade. CONCLUSION: As adjunctive therapy, the combination of lifestyle changes and metformin was found to be a safe strategy for improving related metabolic markers and increasing adiponectin. The BIRADS grade was significantly correlated with the positive pathological biopsy rate and AD, and the positive pathological biopsy rate was significantly correlated with the BIRADS grade.
format Online
Article
Text
id pubmed-8572728
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-85727282021-11-10 Effect of Metformin on Breast Density in Overweight/Obese Premenopausal Women Leng, Weiling Pu, Danlan Jiang, Juan Lei, Xiaotian Wu, Qinan Chen, Bing Diabetes Metab Syndr Obes Clinical Trial Report BACKGROUND: This study investigated the effects of metformin on breast density in overweight/obese premenopausal women. METHODS: Overweight/obese premenopausal women (n=120) were randomly assigned to the metformin or placebo group, and all women received lifestyle interventions. The outcomes included weight, BMI, FPG, FIN, glucose, HOMA-IR, LDL-C, HDL-C, TG, TC, SBP, DBP, FSH, E, AD, and the BIRADS grade, and the incidence of breast cancer was assessed by pathological biopsy and BIRADS grade greater than 4. RESULTS: In total, 120 overweight/obese women completed the 1-year trial. Seven patients had a BIRADS grade greater than 4, including 5 patients who were biopsy positive, in the control group, and 2 patients had a BIRADS grade greater than 4, including 1 patient who was biopsy positive, in the metformin group. Compared with those in the control group, the body weight, BMI, FIN, FPG, HOMA-IR, TC, BIRADS grade and positive pathological biopsy rate in the metformin group were significantly decreased (P<0.05), while AD was significantly increased (P<0.05). The correlation analysis indicated that the BIRADS grade was significantly correlated with weight, BMI, FPG, FIN, HOMA-IR, SBP, AD and the positive pathological biopsy rate, and the positive pathological biopsy rate was significantly correlated with weight, BMI, HOMA-IR, SBP, AD and BIRADS grade. The logistic regression analysis revealed that the BIRADS grade was significantly correlated with the positive pathological biopsy rate and AD and that the positive pathological biopsy rate was significantly correlated with the BIRADS grade. CONCLUSION: As adjunctive therapy, the combination of lifestyle changes and metformin was found to be a safe strategy for improving related metabolic markers and increasing adiponectin. The BIRADS grade was significantly correlated with the positive pathological biopsy rate and AD, and the positive pathological biopsy rate was significantly correlated with the BIRADS grade. Dove 2021-11-03 /pmc/articles/PMC8572728/ /pubmed/34764661 http://dx.doi.org/10.2147/DMSO.S330625 Text en © 2021 Leng et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Leng, Weiling
Pu, Danlan
Jiang, Juan
Lei, Xiaotian
Wu, Qinan
Chen, Bing
Effect of Metformin on Breast Density in Overweight/Obese Premenopausal Women
title Effect of Metformin on Breast Density in Overweight/Obese Premenopausal Women
title_full Effect of Metformin on Breast Density in Overweight/Obese Premenopausal Women
title_fullStr Effect of Metformin on Breast Density in Overweight/Obese Premenopausal Women
title_full_unstemmed Effect of Metformin on Breast Density in Overweight/Obese Premenopausal Women
title_short Effect of Metformin on Breast Density in Overweight/Obese Premenopausal Women
title_sort effect of metformin on breast density in overweight/obese premenopausal women
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572728/
https://www.ncbi.nlm.nih.gov/pubmed/34764661
http://dx.doi.org/10.2147/DMSO.S330625
work_keys_str_mv AT lengweiling effectofmetforminonbreastdensityinoverweightobesepremenopausalwomen
AT pudanlan effectofmetforminonbreastdensityinoverweightobesepremenopausalwomen
AT jiangjuan effectofmetforminonbreastdensityinoverweightobesepremenopausalwomen
AT leixiaotian effectofmetforminonbreastdensityinoverweightobesepremenopausalwomen
AT wuqinan effectofmetforminonbreastdensityinoverweightobesepremenopausalwomen
AT chenbing effectofmetforminonbreastdensityinoverweightobesepremenopausalwomen